Yarrow Bioscience Announces Closing of its $172.5 Million Underwritten Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Vyne Therapeutics Inc YARW
$25.54
▼ -2.03%
($-0.53)
⬇️ Below Yest. Low
🎢 High Beta
Open
$26.98
Prev Close
$26.07
Day Range
$25.01 – $27.13
52W Range
$24.00 – $44.28
Market Cap
$1.09B
EPS (TTM)
$-21.85
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2018-01-25 |
| Shares Out. | 33,390,000 |
| Website | vynetherapeutics.com/ ↗ |
| Phone | 18007757936 |
About Vyne Therapeutics Inc
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.
Vyne Therapeutics Inc is a publicly traded company under the ticker symbol YARW on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
9 analysts (2026-09-01)